Displaying 25 (all) recruiting clinical trials.
-
A Phase 1/2a Multicenter Open-Label First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1305 in Subjects with Advanced/Metastatic Solid Tumors
This is a multicenter, non-randomized, open-label, multiple-dose, first in human (FIH) study. The study consists of two parts: Part 1 adopts an accelerated titration at ...Phase
Interventional
-
PHASE I/II STUDY LADARIXIN AND SOTORASIB IN ADVANCED KRAS G12C MUTANT NON-SMALL CELL LUNG CANCER (NSCLC).
This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in subjects with advanced KRAS G12C mutant NSCLC.Phase
Interventional
-
AN OPEN-LABEL MULTICENTER PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AB-2100 IN PATIENTS WITH RECURRENT ADVANCED OR METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCRCC)
This is an open-label, multicenter Phase 1/2 study evaluating the safety, efficacy, cellular kinetics, immunogenicity, and pharmacodynamics of AB-2100 in adult subjects with recurrent ...Phase
Interventional
-
A Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
TNG908 is a potent and selective oral small molecule inhibitor of PRMT5 that binds cooperatively with MTA to inhibit PRMT5 function. Elevated levels of MTA ...Phase
Interventional
-
An Open-label Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of TAK-500 a Novel Stimulator of Interferon Genes Agonist as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
TAK-500-1001 is a phase 1/2, open-label, dose escalation and expansion study designed to determine the safety, tolerability, antitumor activity, pharmacokinetics (PK), pharmacodynamics, and preliminary ...Phase
Interventional
